Remimazolam : Execution of the extended license agreement for 6 major SE Asian countries between Hana Pharm and Paion AG, Germany in January
2019
Remimazolam : Submission of NDA accepted by MFDS, Korea in December
Initiated P1 of MRI contrast agent
Investment of Injectable Plant, EU & J GMP facility for exports abroad (KRW 58.5bn)
Investment of new site to Pyeongtaek Dream Tech industrial complex (KRW 29.8bn)
2018
Remimazolam : P3 study completed in October
Selection and implementation of governmental tasks on the development of novel drug having VEGF(R) inhibitory properties for diabetic retinopathy. (Ministry of Health & Welfare)
Selection and implementation of governmental tasks on biolipid's interactomics research center. (Ministry of Science and ICT)
2017
Release of anti-emetic Paloxi Inj. (Palonosetron)
2017 sales of 139.3 billion won (11% growth from the previous year)
Release of narcotic analgesics Ocodone Inj. (Oxycodone)
Development of new MRI contrast media “Gd-proton project (HNP-2006)”
2016
2016 sales of 125.2 billion won (16% growth from the previous year)
Finished product warehouse / DPS room expansion
Opening of Pangyo R&D Center
2015
2015 sales of 108.3 billion won (22% growth from the previous year) Prefilled Syringe
Expansion of prefilled syringe production line
2014
2014 sales of 89 billion won (9% growth from the previous year)
Release of narcotic analgesic Remiva Inj. (Remifentanil)
2013
2013 sales of 81.6 billion won (11% growth from the previous year)
New drug Remimazolam partnership with Paion of Germany
Expansion of lyophilized injection production line
2012
2012 sales of 74.1 billion won
2011
2011 sales of 80.5 billion won (2% growth from the previous year)
Release of anti-emetic Ramset Inj. (Ramosetron)
2010
2010 sales of 79.4 billion won (37% growth from the previous year)
Completion of Hagil Central Laboratory
Co-promotion of a new drug Precedex Inj. (Dexmedetomidine) with Hospira of USA
2009
2009 sales of 58.1 billion won (35% growth from the previous year)
Release of narcotic analgesics Ocodone CR (Oxycodone)
2008
2008 sales of 43 billion won (4% growth from the previous year)
Change of Hana Pharm CI
Release of inhalation anesthetic (Sevoflurane) and Ifran Liq. (Isoflurane)
2007
2007 sales of 41.4 billion won (12% growth from the previous year)
Completion of Hagil factory of state-of-the-art facility of EU GMP level
2006
2006 sales of 37 billion won (8% growth from the previous year)
Domestic release of inhalation anesthetic Terrell (Isoflurane) and Compound347 (Enflurane)
Export of Anepol Inj. (Propofol) to Indonesia
New establishment of laboratory
2005
2005 sales of 34.2 billion won (17% growth from the previous year)
Export contract of Anepol Inj.(propofol) and Atra Inj.(Atracurium) to China
Supply contract of inhalation anesthetic with MINRAD of USA
2004
2004 sales of 29.3 billion won (26% growth from the previous year)
Export of Anepol Inj. (Propofol) to Vietnam
Expansion of the Central Laboratory
Designation as the qualified BGMP company
Export of Anepol Inj.(Propofol) to Thailand
Export contract of Anepol Inj. (Propofol) and Atra Inj.(Atracurium) to Russia
2003
Completion of Hyangnam factory (drug substance synthesis factory), expansion of the Central Laboratory
Export of Anepol Inj. (Propofol) to Brazil
2002
Export of Cenital tab. (Aceclofenac) to Vietnam
Export contract of Anepol Inj. (Propofol) to Indonesia
First domestic release of Fentas Patch (narcotic analgesic patch)
2001
Export contract of Anepol Inj. (Propofol) to Brazil
2000
Export of Kepiten tab. (Ketotifen) and Bacylovir cream (Acyclovir) to Hong Kong
Export of Cafenac SR (Diclofenac) to Pakistan
1999
Release of Anepol Inj. (Propofol)
Completion of the Central Laboratory (attached synthesis room)
1998
Establishment of the Central Laboratory
1997
Expansion of Hyangnam Factory
Market release of injections (narcotic analgesics, muscle relaxants, etc.)